Fig. 2: The LC is necessary for naloxone-induced morphine withdrawal behaviours.
A Schematic depicting experimental timeline for intracerebral LC administration of lidocaine (Lido, 1%), Mac-1-saporin (Mac-1-sap, 15 µg), 10Panx (10 µg) and apyrase (10 units). B–E Effects of intra-LC administration of various compounds on cumulative withdrawal scores during naloxone-precipitated withdrawal. B intra-LC lidocaine (Mann–Whitney two-sided test, p = 0.0079, SAL: N = 4, Lido: N = 5 mice), C mac-1-sap (unpaired two-sided t-test, p = 0.010, Sap: N = 3 mice, mac-1-sap: N = 4 mice), D 10Panx (unpaired two-sided t-test, p = 0.001, scrPanx and 10Panx: N = 6) and E apyrase (APR) (Mann–Whitney two-sided test, p = 0.0095, Sal: N = 4, apyrase: N = 6 mice). Representative images and quantification of cFos immunoreactivity after intra-LC (F) Lido (unpaired two-sided t-test, p = 0.0022, SAL: N = 4, Lido: N = 6 mice), (G) mac-1-sap (unpaired two-sided t-test, p = 0.0143, sap: N = 8, mac-1-sap: N = 6 mice), (H) 10Panx (unpaired two-sided t-test, p = 0.0011, scrpanx and 10Panx: N = 8 mice) and (I) apyrase (unpaired two-sided t-test, p = 0.0009, SAL: N = 5, apyrase: N = 6 mice). All graphed data are presented as mean values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
